Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma

Interventions

DRUG: Vincristine
DRUG: Dactinomycin
DRUG: Cyclophosphamide
PROCEDURE: Surgical Resection
PROCEDURE: Proton beam radiation or external beam radiation or brachytherapy
DRUG: Liposomal irinotecan
DRUG: Vinorelbine
DRUG: Temozolomide
DRUG: Filgrastim, peg-filgrastim

Sponsor

St. Jude Children's Research Hospital